Phase II
CytoDyn announced two separate stories about its drug leronlimab today, one for nonalcoholic steatohepatitis and the other for metastatic triple-negative breast cancer.
An announcement lit up the global grapevine today as Clene Nanomedicine released the results from Phase II of their RESCUE-ALS clinical trial.
This lipid-based system is able to tightly target antigen-presenting cells and thus trigger a rapid, persistent and robust T cell response against various cancers.
Yet another busy week for clinical trial news. Here’s a look.
The 643-participant study failed to reach statistical significance in its co-primary cognitive and functional endpoints, ADAS-Cog11 and ADCS-ADL, at end of treatment.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
Initial results showed a strong neutralizing antibody response and favorable safety profile among the participants.
It was yet another busy week for clinical trial news. Here’s a look.
Late Thursday, Athira announced that Kawas had resigned from her position as CEO and president of the company.
The FDA placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.
PRESS RELEASES